Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Parallel Phase I Study Evaluating Multiple Ascending Dose Pharmacokinetics and Acute Immunomodulatory Potential of a Novel Oral Cannabidiol (CBD) Formulation

NCT06286839 is registered in ClinicalTrials.gov with NextEvo Inc. as lead sponsor.

NCT NCT06286839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06286839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Parallel Phase I Study Evaluating Multiple Ascending Dose Pharmacokinetics and Acute Immunomodulatory Potential of a Novel Oral Cannabidiol (CBD) Formulation
Lead sponsor
NextEvo Inc.
Phase
Not applicable
Overall status
Completed
Start date
May 12, 2022
Completion date
December 14, 2022
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune system and related disorders, immune system diseases